{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T10:46:06Z","timestamp":1789296366830,"version":"build-2803163510"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by reinvigorating antitumor immunity through the blockade of inhibitory pathways such as programmed cell death protein 1 (PD-1)\/programmed cell death protein ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Despite their remarkable clinical success, only a subset of patients derives durable benefit, whereas others exhibit primary or acquired resistance and develop immune-related adverse events (irAEs). These heterogeneous responses highlight an urgent need for robust biomarkers to predict therapeutic efficacy and for innovative combinatorial strategies to enhance clinical outcomes. Beyond their classical roles in hemostasis and thrombosis, platelets have recently emerged as pivotal modulators of tumor progression and immune regulation. Accumulating evidence indicates that platelets engage in dynamic crosstalk with tumor and immune cells, reshaping the tumor microenvironment (TME) and modulating the response to ICI therapy. Of note, platelet-associated immune checkpoint molecules (e.g., PD-L1) have shown great promise as liquid biopsy markers for patient stratification and real-time immunomonitoring. Furthermore, platelet-associated nucleic acids and traditional platelet parameters (such as platelet count and activation status) have been identified as accessible and effective biomarkers for predicting ICI responsiveness and irAEs. These platelet-derived components may also represent novel therapeutic targets to overcome resistance and potentiate ICI efficacy. Meanwhile, advances in biomaterials and genetic engineering have further enabled the development of platelet-based and platelet membrane (PM)-camouflaged delivery systems endowed with tumor-homing capacity, combinatorial drug delivery potential, and immune-responsive release properties. Collectively, these insights reposition platelets from passive participants to active regulators and versatile therapeutic platforms in cancer immunotherapy, providing a conceptual foundation for next-generation platelet-guided precision immunotherapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1764513","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:19Z","timestamp":1777009399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From escort to target, the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiayu","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaru","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences (CAS) Center for Excellence in Nanoscience, National Center for Nanoscience and Technology","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhen","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0065-2776(06)90008-x","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.01.161","article-title":"Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial","volume":"55","author":"Merle","year":"2023","journal-title":"Dig Liver Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00976-x","article-title":"Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer","volume":"22","author":"Cascone","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41571-024-00978-9","article-title":"Ipilimumab plus nivolumab efficacious in patients with dMMR\/MSI-H disease","volume":"22","author":"Sidaway","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae470","article-title":"The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting","volume":"192","author":"Karine","year":"2024","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26663","article-title":"Role of immune system in tumor progression and carcinogenesis","volume":"119","author":"Upadhyay","year":"2018","journal-title":"J Cell Biochem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545284","article-title":"Immune cells differentiation in osteoarthritic cartilage damage: friends or foes","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Figure Haddad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.012","article-title":"Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer","volume":"147","author":"Ben Dori","year":"2020","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.017","article-title":"PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections","volume":"13","author":"Munari","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj\/mn\/7800123","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"Microcirculation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.3.1325","article-title":"MicroRNA-513 regulates B7-H1 translation and is involved in IFN-\u03b3-induced B7-H1 expression in cholangiocytes","volume":"182","author":"Gong","year":"2009","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41467-020-15364-z","article-title":"NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer","volume":"11","author":"Qin","year":"2020","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-3206","article-title":"Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.01.006","article-title":"Surgery-mediated tumor-promoting effects on the immune microenvironment","volume":"86","author":"Cheng","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321861","article-title":"Mechanism of tumor-platelet communications in cancer","volume":"132","author":"Dudiki","year":"2023","journal-title":"Circ Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp3971","article-title":"Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA","volume":"389","author":"Murphy","year":"2025","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1786387","article-title":"Platelet physiology","volume":"50","author":"Gremmel","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The platelet lifeline to cancer: challenges and opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02793-4","article-title":"Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents","volume":"70","author":"Zamora","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0202-z","article-title":"Patrolling the vascular borders: platelets in immunity to infection and cancer","volume":"19","author":"Figure Gaertner","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-29","article-title":"PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer","volume":"13","author":"Hu","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.965033","article-title":"Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Genet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12885-024-12006-1","article-title":"Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets","volume":"24","author":"Da","year":"2024","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-022-00021-z","article-title":"A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences","volume":"1","author":"Tyagi","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00018-024-05526-3","article-title":"Platelet stimulation-regulated expression of ILK and ITGB3 contributes to intrahepatic cholangiocarcinoma progression through FAK\/PI3K\/AKT pathway activation","volume":"82","author":"Yao","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1406","article-title":"The angiogenic responses induced by release of angiogenic proteins from tumor cell-activated platelets are regulated by distinct molecular pathways","volume":"67","author":"Wu","year":"2015","journal-title":"IUBMB Life"},{"key":"B47","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/thno.64252","article-title":"Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior","volume":"12","author":"Rodriguez-Martinez","year":"2022","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8188","article-title":"Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.1078197","article-title":"Synthesis of serotonin by a second tryptophan hydroxylase isoform","volume":"299","author":"Walther","year":"2003","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s13258-022-01291-4","article-title":"Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion","volume":"44","author":"Wang","year":"2022","journal-title":"Genes Genomics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102498","article-title":"Platelets increase the expression of PD-L1 in ovarian cancer","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15478","article-title":"Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs","volume":"19","author":"Asgari","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B55","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/hep.0000000000000934","article-title":"Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT","volume":"81","author":"Sun","year":"2025","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260124","article-title":"PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer","volume":"16","author":"Darga","year":"2021","journal-title":"PloS One"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115709","article-title":"High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab","volume":"168","author":"Colarusso","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2024.343312","article-title":"Mass-tagged self-assembled nanoprobe reveals the transport of PD-L1 from cancer cells to tumor-educated platelets","volume":"1331","author":"Zhu","year":"2024","journal-title":"Anal Chim Acta"},{"key":"B60","doi-asserted-by":"publisher","first-page":"19296","DOI":"10.1038\/s41598-020-76351-4","article-title":"Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors","volume":"10","author":"Zaslavsky","year":"2020","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.11.014","article-title":"Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: A systematic review","volume":"414","author":"Teng","year":"2018","journal-title":"Cancer Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18062","article-title":"Platelets modulate CD4(+) T-cell function in COVID-19 through a PD-L1 dependent mechanism","volume":"197","author":"Paletta","year":"2022","journal-title":"Br J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.109056","article-title":"Platelet PD-L1 inhibits storage-induced apoptosis by sustaining activation of the AKT signalling pathway","volume":"240","author":"Chen","year":"2024","journal-title":"Thromb Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205200","article-title":"PD-L1 expression on circulating tumour-derived microvesicles as a complementary tool for stratification of high-grade serous ovarian cancer patients","volume":"13","author":"Battaglia","year":"2021","journal-title":"Cancers"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2727-4","article-title":"Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease","volume":"371","author":"Lisman","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1038\/ncomms6256","article-title":"Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein","volume":"5","author":"Yu","year":"2014","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3222","article-title":"Platelet TLR4-ERK5 axis facilitates NET-mediated capturing of circulating tumor cells and distant metastasis after surgical stress","volume":"81","author":"Ren","year":"2021","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1615\/CritRevImmunol.2023047234","article-title":"Tregs and platelets play synergistic roles in tumor immune escape and inflammatory diseases","volume":"42","author":"Gao","year":"2022","journal-title":"Crit Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2015-06-649434","article-title":"Circular RNA enrichment in platelets is a signature of transcriptome degradation","volume":"127","author":"Alhasan","year":"2016","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751099","article-title":"Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth","volume":"130","author":"Michael","year":"2017","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344408","article-title":"Blood platelets contain tumor-derived RNA biomarkers","volume":"118","author":"Nilsson","year":"2011","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003978","article-title":"Platelets and tumor-associated RNA transfer","volume":"137","author":"D\u2019Ambrosi","year":"2021","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02175-9","article-title":"Platelets","volume":"355","author":"George","year":"2000","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2797","article-title":"Transcript profiling of human platelets using microarray and serial analysis of gene expression","volume":"101","author":"Gnatenko","year":"2003","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324517","article-title":"Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events","volume":"118","author":"Cecchetti","year":"2011","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat Cell Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3015","article-title":"The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"McAllister","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001623","article-title":"Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1\u03b2-rich microparticles","volume":"186","author":"Brown","year":"2011","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9674-0","article-title":"Platelet RNA signatures for the detection of cancer","volume":"36","author":"Sol","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-18-0887","article-title":"Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring","volume":"78","author":"Best","year":"2018","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-022-00185-9","article-title":"Genetic analysis of platelet-related genes in hepatocellular carcinoma reveals a novel prognostic signature and determines PRKCD as the potential molecular bridge","volume":"24","author":"Li","year":"2022","journal-title":"Biol Proced Online"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1187700","article-title":"A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204886","article-title":"Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma","volume":"15","author":"Zhao","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S363200","article-title":"Platelet-related molecular subtype to predict prognosis in hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.21037\/tau-24-80","article-title":"A platelet-related signature for predicting the prognosis and immunotherapy benefit in bladder cancer based on machine learning combinations","volume":"13","author":"Chen","year":"2024","journal-title":"Transl Androl Urol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-743229","article-title":"Mechanisms of platelet clearance and translation to improve platelet storage","volume":"131","author":"Quach","year":"2018","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.41633","article-title":"Analysis of platelet count and new cancer diagnosis over a 10-year period","volume":"5","author":"Giannakeas","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003370","article-title":"Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"9","author":"Pietrantonio","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100075","article-title":"Retrospective evaluation of the use of pembrolizumab in Malignant mesothelioma in a real-world Australian population","volume":"1","author":"Ahmadzada","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2020-0021","article-title":"Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy","volume":"6","author":"Assi","year":"2020","journal-title":"Future Sci OA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.043","article-title":"The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors","volume":"150","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-022-03359-x","article-title":"Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma","volume":"20","author":"Guida","year":"2022","journal-title":"J Transl Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00432-024-05997-8","article-title":"Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482746","article-title":"Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"15","author":"Ou","year":"2024","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2280002","article-title":"Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors","volume":"55","author":"Cao","year":"2023","journal-title":"Ann Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408700","article-title":"Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"15","author":"Tan","year":"2024","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34229","article-title":"Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study","volume":"128","author":"Sheshadri","year":"2022","journal-title":"Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i11.1900","article-title":"Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma","volume":"15","author":"Dharmapuri","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1510053","article-title":"Development and validation of a nomogram for predicting immune-mediated colitis in lung cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study in China","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024230","article-title":"Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling","volume":"144","author":"Dei Zotti","year":"2024","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031449","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"147","author":"Leaf","year":"2025","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02385.x","article-title":"Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity","volume":"103","author":"Kaneko","year":"2012","journal-title":"Cancer Sci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","author":"Suzuki-Inoue","year":"2019","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1370","article-title":"Platelets: guardians of tumor vasculature","volume":"69","author":"Ho-Tin-Noe","year":"2009","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003655","article-title":"Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies","volume":"10","author":"Lutz","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900594","article-title":"Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade","volume":"203","author":"Riesenberg","year":"2019","journal-title":"J Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/0008-5472.CAN-19-1181","article-title":"The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis","volume":"80","author":"Plantureux","year":"2020","journal-title":"Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1209846","article-title":"In vitro cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a Malicious association during the harsh journey in the blood","volume":"11","author":"Eslami","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13046-023-02856-1","article-title":"Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of Malignant melanoma by triggering macrophage recruitment","volume":"42","author":"Chen","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0461","article-title":"A hypoxia-inducible HIF1-GAL3ST1-sulfatide axis enhances ccRCC immune evasion via increased tumor cell-platelet binding","volume":"17","author":"Robinson","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1161\/01.Atv.0000149675.83552.83","article-title":"Sulfatides activate platelets through P-selectin and enhance platelet and platelet-leukocyte aggregation","volume":"25","author":"Merten","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13058-018-1058-z","article-title":"Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression","volume":"20","author":"Suchanski","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"15477","DOI":"10.1038\/s41598-021-94735-y","article-title":"Interactions of platelets with circulating tumor cells contribute to cancer metastasis","volume":"11","author":"Anvari","year":"2021","journal-title":"Sci Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03387.x","article-title":"Selective sorting of alpha-granule proteins","volume":"7","author":"Italiano","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113837","article-title":"Angiogenesis is regulated by a novel mechanism:: pro- and antiangiogenic proteins are organized into separate platelet \u03b1 granules and differentially released","volume":"111","author":"Italiano","year":"2008","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2003.03446.x","article-title":"The subtle side to hypoxia inducible factor (HIFalpha) regulation","volume":"270","author":"Bilton","year":"2003","journal-title":"Eur J Biochem"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081947","article-title":"Platelet-derived PDGFB promotes recruitment of cancer-associated fibroblasts, deposition of extracellular matrix and Tgf\u03b2 signaling in the tumor microenvironment","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.12.071","article-title":"Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates","volume":"45","author":"Yokoyama","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1901987116","article-title":"Perfluorocarbon nanoparticle-mediated platelet inhibition promotes intratumoral infiltration of T cells and boosts immunotherapy","volume":"116","author":"Zhou","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202304374","article-title":"Fibrinolytic platelet decoys reduce cancer metastasis by dissociating circulating tumor cell clusters","volume":"13","author":"Schnoor","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"B135","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s40164-025-00723-7","article-title":"Targeting platelet-tumor cell interactions via thromboxane A(2)-prostanoid receptor blockade to reduce metastasis in triple negative breast cancer","volume":"14","author":"Toragall","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2023.04.002","article-title":"Comprehensive analysis of glycoprotein VI-mediated platelet activation signaling pathway for predicting pan-cancer survival and response to anti-PD-1 immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"Comput Struct Biotechnol J"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192079","article-title":"Standardization and reference ranges for whole blood platelet function measurements using a flow cytometric platelet activation test","volume":"13","author":"Huskens","year":"2018","journal-title":"PloS One"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.08.015","article-title":"Platelet activation in patients with peripheral vascular disease: reproducibility and comparability of platelet markers","volume":"129","author":"Burdess","year":"2012","journal-title":"Thromb Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5898","article-title":"Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models","volume":"11","author":"Papa","year":"2019","journal-title":"Sci Transl Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106301","article-title":"Targeting glycoprotein VI to disrupt platelet-mediated tumor cell extravasation","volume":"182","author":"Tesfamariam","year":"2022","journal-title":"Pharmacol Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706013","article-title":"Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation","volume":"143","author":"Jurasz","year":"2004","journal-title":"Br J Pharmacol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3164","article-title":"P-selectin-mediated platelet adhesion promotes tumor growth","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.05.008","article-title":"Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody","volume":"304","author":"Han","year":"2019","journal-title":"J Control Release"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf6854","article-title":"Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv Mater"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.05.045","article-title":"Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy","volume":"371","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.10.003","article-title":"Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia","volume":"111","author":"Wei","year":"2016","journal-title":"Biomaterials"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd7614","article-title":"Near-infrared light-triggered platelet arsenal for combined photothermal-immunotherapy against cancer","volume":"7","author":"Lv","year":"2021","journal-title":"Sci Adv"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150318","article-title":"Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience","volume":"113","author":"Bieker","year":"2009","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.4c00293","article-title":"Engineering cells for cancer therapy","volume":"57","author":"Liu","year":"2024","journal-title":"Acc Chem Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.213796","article-title":"Engineered platelet-based immune engager for tumor post-surgery treatment","volume":"158","author":"Chen","year":"2024","journal-title":"Biomater Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:43:20Z","timestamp":1777009400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":156,"alternative-id":["10.3389\/fimmu.2026.1764513"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1764513","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1764513"}}